Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 2, 2001, Pages 382-392

  Desta, Z ^a   Soukhova, N V ^a   Flockhart, D A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 ISOENZYME; DIAZEPAM; ISONIAZID; PHENYTOIN; PRIMIDONE; TRIAZOLAM;

ACETYLATOR PHENOTYPE; ARTICLE; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MIXTURE; DRUG POTENTIATION; ENZYME INACTIVATION; ENZYME POLYMORPHISM; ENZYME SUBSTRATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER MICROSOME; NEUROTOXICITY; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SIDE EFFECT;

ALGORITHMS; ANTITUBERCULAR AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; ISONIAZID; KINETICS; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES, N-DEMETHYLATING; RECOMBINANT PROTEINS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 0035144768     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.2.382-392.2001     Document Type: Article

References (61)

1. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite
2. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
3. Diphenylhydantoin intoxication attendant to slow inactivation of isoniazid
4. Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity
5. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver
6. Effect of isoniazid on the metabolism of 14C-diphenylhydantoin in rats
7. Pharmacokinetic drug interactions of vinca alkaloids: Summary of case reports
8. Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization
9. Treatment and prevention of tuberculosis in HIV-infected persons
10. Acetaminophen hepatotoxicity: Potentiation by isoniazid
11. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide
12. Ticlopidine inhibits phenytoin clearance
13. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19
14. Genetic control of isoniazid metabolism in man
15. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19
16. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily
17. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis
18. Clinically significant drug interactions with antituberculosis agents
19. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme
20. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes
21. Influence of rifampicin and isoniazid on the kinetics of phenytoin
22. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: Potent effect on CYP2C19 and CYP2D6
23. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms
24. Diphenylhydantoin intoxication. A complication of isoniazid therapy
25. Metabolism of diphenylhydantoin by rat liver microsomes. I. Characteristics of the reaction
26. Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide. S-mephenytoin, and omeprazole hydroxylations
27. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress
28. Cytochrome P450 isoenzymes and antiepileptic drug interactions
29. The role of CYP2c19 in the formation of nelfinavir hydroxy-butylamide (M8): In vitro/in vivo correlation
30. Clinical importance of the interaction of phenytoin and isoniazid: A report from the Boston Collaborative Drug Surveillance Program
31. Cytochrome P4502C9: An enzyme of major importance in drug metabolism
32. Cross-matching TB and AIDS registries: TB patients with HIV co-infection, United States 1993-1994
33. Role of cytochrome P4502E1 in alcoholic liver disease pathogenesis
34. Mechanism of the inhibitory action of isoniazid on microsomal drug metabolism
35. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis
36. Diazepam interaction with antituberculosis drugs
37. Differential effect of isoniazid on triazolam and oxazepam conjugation
38. Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators
39. Inhibition of leukotriene omega-oxidation by isonicotinic acid hydrazide (isoniazid)
40. Hydroxylation of chlorzoxazone as a specific probe of cytochrome P450 IIE1
41. Application of Bradford's assay to adrenal gland subcellular fractions
42. Polymorphic drug metabolism
43. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily
44. Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor
45. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients
46. Isoniazid drug and food interactions
47. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6
48. Isoniazid as an inhibitor of primidone metabolism
49. Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2
50. Ticlopidine decreases the in vitro activity of CYP2C19 as measured by omeprazole metabolism
51. Use of midazolam as a human cytochrome P450 3A probe. I. In vitro-in vivo correlations in liver transplant patients
52. Isoniazid and ethionamide serum levels and inactivation in Finnish subjects
53. Studies of flurbiprofen 4′ hydroxylation: Additional evidence suggesting the sole involvement of cytochrome P450 2C9
54. Carbamazepine intoxication caused by interaction with isoniazid
55. Ethosuximide intoxication caused by interaction with isoniazid
56. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A
57. Clinical pharmacokinetics of isoniazid
58. Isoniazid-induced carbamazepine toxicity and vice versa: A double drug interaction
59. Carbamazepine-isoniazid interaction
60. Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation
61. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans